NovaBridge Biosciences (NBP) Accumulated Expenses (2018 - 2025)

NovaBridge Biosciences (NBP) has 8 years of Accumulated Expenses data on file, last reported at $2.8 million in Q4 2025.

• Quarterly Accumulated Expenses rose 1404.23% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 1404.23% YoY) and the FY2025 annual result came in at $2.8 million, up 1404.23% from the prior year.
• Accumulated Expenses declined to $2.8 million in Q4 2025 per NBP's latest filing, from $7.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $92.8 billion in Q4 2021 and bottomed at -$7.3 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $6.8 million (2023), against an average of $7.2 billion.
• The widest annual swing landed in 2021, when Accumulated Expenses jumped 109616.73%; it then sank 137.78% in 2025.
• Tracing NBP's Accumulated Expenses over 5 years: stood at $92.8 billion in 2021, then tumbled by 99.99% to $6.1 million in 2022, then climbed by 10.41% to $6.8 million in 2023, then plunged by 103.16% to -$213000.0 in 2024, then surged by 1404.23% to $2.8 million in 2025.
• Per Business Quant, the three latest NBP Accumulated Expenses figures stand at $2.8 million (Q4 2025), $7.4 million (Q3 2025), and -$1.3 million (Q2 2025).

Peer Comparison